FDA Postdoctoral Fellowship - Enhancing Safety and Efficacy of Immune Cell and Gene Therapies

U.S. Food and Drug Administration (FDA)

FDA-CBER-

12/31/2026 11:59:00 PM Eastern Time Zone

Applications will be reviewed on a rolling-basis.

A research opportunity is currently available at the Center for Biologics Evaluation and Research (CBER), in the Office of Therapeutic Products (OTP), at the Food and Drug Administration (FDA) in Silver Spring, Maryland.

The Center for Biologics Evaluation and Research (CBER) is one Center within the Food and Drug Administration, an Agency within the United States Government's Department of Health and Human Services. CBER's mission is to protect and enhance the public health through the regulation of biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies.

CBER’s mission is to ensure the safety, purity, potency, and effectiveness of biological products including vaccines, blood and blood products, and cells, tissues, and gene therapies for the prevention, diagnosis, and treatment of human diseases, conditions, or injury. In joining this CBER laboratory you will join research projects related to cell and gene therapy. You will use advanced manufacturing tools and strategies to gain a deeper understanding of challenges associated with T cell-based immunotherapies such as CAR-T cells and develop novel strategies to improve safety and efficacy of T cell therapies.

• Will learn to perform laboratory research on projects related to cell and gene therapy.
• Will learn to use advanced manufacturing tools and strategies to gain a deeper understanding of challenges associated with T cell-based immunotherapies (such as CAR-T cells).
• Will learn to develop novel strategies to improve safety and efficacy of T cell therapies.

The mentor for this opportunity is Fei Mo (Fei.Mo.gov) If you have questions about the nature of the research, please contact the mentor.

2026. Start date is flexible and will depend on a variety of factors.

The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

The appointment is full time.

The participant will receive a monthly stipend commensurate with educational level and experience.

This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the Guidelines for Non-U.S. Citizens Details page of the program website for information about the valid immigration statuses that are acceptable for program participation.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded  can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or…